The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

@article{SnchezMartn2016TheFA,
  title={The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.},
  author={Francisco J. S{\'a}nchez-Mart{\'i}n and Beatriz Bellosillo and Mariona Gelabert-Baldrich and Alba Dalmases and Israel Ca{\~n}adas and Jorgiano M. B. Vidal and Alejandro Mart{\'i}nez and Guillem Argil{\'e}s and Giulia Siravegna and Sabrina Arena and Klaus Koefoed and Laura Visa and Oriol Arp{\'i} and Ivan David Horak and Mari{\'a}ngeles Iglesias and Christopher Stroh and Mikkel K. Kragh and Albert Feliu Rovira and J 1137 Albanell and Josep Tabernero and Alberto Bardelli and Clara Montagut},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2016},
  volume={22 13},
  pages={
          3260-7
        }
}
PURPOSE Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often driven by acquisition of mutations in the extracellular domain (ECD) of EGFR. Sym004 is a novel 1:1 mixture of two nonoverlapping anti-EGFR mAbs that recently showed promising clinical activity in a phase I trial in MCRC. Our aim was to determine the efficacy of Sym004 to… CONTINUE READING
Tweets
This paper has been referenced on Twitter 11 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Similar Papers

Loading similar papers…